{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:40:28Z","timestamp":1793094028078,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>The rapid and global spread of a new human coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Here, we consider drug repurposing as an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. We review current information concerning the global health issue of COVID-19 including promising approved drugs, e.g., human angiotensin-converting enzyme inhibitors (<jats:italic>h<\/jats:italic>ACEIs). Besides, we describe computational approaches to be used in drug repurposing and highlight examples of <jats:italic>in-silico<\/jats:italic> studies of drug development efforts against SARS-CoV-2. Alacepril and lisinopril were found to interact with human angiotensin-converting enzyme 2 (<jats:italic>h<\/jats:italic>ACE2), the host entranceway for SARS-CoV-2 spike protein, through exhibiting the most acceptable rmsd_refine values and the best binding affinity through forming a strong hydrogen bond with Asn90, which is assumed to be essential for the activity, as well as significant extra interactions with other receptor-binding residues. Furthermore, molecular dynamics (MD) simulations followed by calculation of the binding free energy were also carried out for the most promising two ligand-pocket complexes from docking studies (alacepril and lisinopril) to clarify some information on their thermodynamic and dynamic properties and confirm the docking results as well. These results we obtained probably provided an excellent lead candidate for the development of therapeutic drugs against COVID-19. Eventually, animal experiments and accurate clinical trials are needed to confirm the potential preventive and treatment effect of these compounds.<\/jats:p>","DOI":"10.3389\/fchem.2021.661230","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:05:12Z","timestamp":1620104712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":249,"title":["Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor"],"prefix":"10.3389","volume":"9","author":[{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Dahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Metwaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh S.","family":"Elhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam B.","family":"Elkaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled M.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105510","DOI":"10.1016\/j.ejps.2020.105510","article-title":"Biological evaluation and molecular modeling of peptidomimetic compounds as inhibitors for O-GlcNAc transferase (OGT)","volume":"154","author":"Albuquerque","year":"2020","journal-title":"Eur. J. Pharm. Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.34172\/PS.2021.3","article-title":"Molecular docking dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease","author":"Al-Karmalawy","year":"","journal-title":"Pharm Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13990","DOI":"10.1039\/D0NJ02844D","article-title":"Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor","volume":"44","author":"Al-Karmalawy","year":"2020","journal-title":"N. J. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e05641","DOI":"10.1016\/j.heliyon.2020.e05641","article-title":"Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease","volume":"6","author":"Alnajjar","year":"2020","journal-title":"Heliyon"},{"key":"B5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Disc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02435-4","article-title":"Energetics and IC50 based epitope screening in SARS CoV - 2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development","volume":"18","author":"Banerjee","year":"2020","journal-title":"J. Trans. Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1021\/jp302103t","article-title":"A comparison of multiscale methods for the analysis of molecular dynamics simulations","volume":"116","author":"Benson","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1021\/ct300400x","article-title":"Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone \u03d5, \u03c8 and sidechain \u03c71 and \u03c72 dihedral angles","volume":"8","author":"Best","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"B9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/v12040445","article-title":"Molecular investigation of SARS\u2013CoV-2 proteins and their interactions with antiviral drugs","volume":"12","author":"Calligari","year":"2020","journal-title":"Viruses"},{"key":"B10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-1-0716-0282-9_16","article-title":"Binding free energy calculation using quantum mechanics aimed for drug lead optimization","volume":"2114","author":"Cavasotto","year":"2020","journal-title":"Quant. Mech. Drug Disc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e01218","DOI":"10.1213\/XAA.0000000000001218","article-title":"Coronavirus disease 2019 situation update","volume":"14","author":"Culp","year":"2021","journal-title":"World Health Organ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1847687","article-title":"Development of parameters compatible with the CHARMM36 force field for [Fe4S4] 2+ clusters and molecular dynamics simulations of adenosine-5'-phosphosulfate reductase in GROMACS 2019","volume":"13","author":"da Silva","year":"2020","journal-title":"J. Biomol. Struct. Dyn"},{"key":"B14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13659-020-00275-9","article-title":"Hordatines as a potential inhibitor of COVID - 19 main protease and RNA polymerase: an in silico approach","volume":"10","author":"Dahab","year":"2020","journal-title":"Nat. Prod. Bioprospect"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: An N\u00b7 log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1998","journal-title":"J. Chem. Phys."},{"key":"B16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cbic.202000455","article-title":"Why does the novel coronavirus spike protein interact so strongly with the human ACE2? A thermodynamic answer","volume":"22","author":"de Andrade","year":"2020","journal-title":"ChemBioChem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.bmcl.2019.02.031","article-title":"3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7","volume":"29","author":"de Souza","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B18","first-page":"82","article-title":"Pymol: an open-source molecular graphics tool","volume":"40","author":"Delano","year":"2002","journal-title":"CCP4 Newslett. Protein Crystallogr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jmii.2020.04.015","article-title":"ScienceDirect ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome","volume":"53","author":"Devaux","year":"2020","journal-title":"J. Microbiol. Immunol. Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0008-6363(00)00163-2","article-title":"Fibrinolytic actions of ACE inhibitors: a significant plus beyond antihypertensive therapeutic effects","volume":"47","author":"D\u00e9zsi","year":"2000","journal-title":"Elsevier Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV \u2014 a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","article-title":"Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mtor pathway and inhibition of calmodulin: in vitro and molecular docking studies","volume":"3","author":"Eliaa","year":"2020","journal-title":"ACS Pharmacol. Trans. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"17374","DOI":"10.1039\/D0NJ04088F","article-title":"Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K\/AKT\/mTOR pathway and inhibition of topoisomerase II: in vitro and molecular docking studies","volume":"44","author":"Ghanem","year":"2020","journal-title":"N. J. Chem."},{"key":"B25","first-page":"611","article-title":"Dynamic attractor for the Berendsen thermostat an the slow dynamics of biomacromolecules","volume":"47","author":"Golo","year":"2002","journal-title":"Biofizika"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-71748-7","article-title":"Analysis of the SARS - CoV - 2 spike protein glycan shield reveals implications for immune recognition","volume":"10","author":"Grant","year":"2020","journal-title":"Sci. Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.yjmcc.2020.04.031","article-title":"SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications","volume":"144","author":"Gro\u00df","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1822208","article-title":"Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia","volume":"16","author":"Helal","year":"2020","journal-title":"J. Biomol. Struct. Dyn"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual Molecular Dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1021\/jz501780a","article-title":"Building water models: a different approach","volume":"5","author":"Izadi","year":"2014","journal-title":"J. Phys. Chem. Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.sjbs.2021.01.040","article-title":"Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations","volume":"28","author":"Jairajpuri","year":"2021","journal-title":"Saudi J. Biol. Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/347631a0","article-title":"Molecular dynamics simulations in biology","volume":"347","author":"Karplus","year":"1990","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1848634","article-title":"Structure-based identification of potential SARS- CoV-2 main protease inhibitors","volume":"19","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn"},{"key":"B37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fchem.2021.628398","article-title":"Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations","volume":"9","author":"Khattab","year":"2021","journal-title":"Front. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"10027","DOI":"10.1039\/D0RA10674G","article-title":"Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study","volume":"11","author":"Khattab","year":"2021","journal-title":"RSC Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"104326","DOI":"10.1016\/j.bioorg.2020.104326","article-title":"Bioorganic chemistry A perspective on potential target proteins of COVID-19: comparison with SARS-CoV for designing new small molecules","volume":"104","author":"Kumar","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa- A GROMACS tool for high-throughput MM-PBSA calculations","volume":"5","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","article-title":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2","volume":"24","author":"Li","year":"2005","journal-title":"EMBO J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1110\/ps.051681605","article-title":"A statistical approach to the interpretation of molecular dynamics simulations of calmodulin equilibrium dynamics","volume":"14","author":"Liki\u0107","year":"2005","journal-title":"Protein Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10822-016-0005-2","article-title":"Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations","volume":"31","author":"Liu","year":"2017","journal-title":"J. Comput. Aided Mol. Des."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040949","article-title":"Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial","author":"Lover","year":"2020","journal-title":"MedRXiv [Preprint]"},{"key":"B45","doi-asserted-by":"publisher","first-page":"198102","DOI":"10.1016\/j.virusres.2020.198102","article-title":"Identification of high-affinity inhibitors of SARS-CoV-2 main protease : Towards the development of effective COVID-19 therapy","volume":"288","author":"Mohammad","year":"2020","journal-title":"Virus Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.RES.86.2.139","article-title":"Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes","volume":"86","author":"Napoleone","year":"2000","journal-title":"Circ. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.cpc.2013.06.003","article-title":"A flexible algorithm for calculating pair interactions on SIMD architectures","volume":"184","author":"P\u00e1ll","year":"2013","journal-title":"Comput. Phys. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e103866","DOI":"10.1371\/journal.pone.0103866","article-title":"Insights from molecular dynamics simulations: structural basis for the V567D mutation-induced instability of zebrafish alpha-dystroglycan and comparison with the murine model","volume":"9","author":"Pirolli","year":"2014","journal-title":"PLoS ONE"},{"key":"B50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1021\/acs.jpcb.7b11734","article-title":"Biomolecular simulations under realistic macroscopic salt conditions","volume":"122","author":"Ross","year":"2019","journal-title":"J. Phys. Chem. B"},{"key":"B52","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1056\/NEJMc2001468","article-title":"Correspondence transmission of 2019-nCoV infection from an asymptomatic contact in Germany","volume":"382","author":"Rothe","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.sajb.2021.02.007","article-title":"Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L","volume":"139","author":"Samra","year":"2021","journal-title":"South Afr. J. Botany"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19) a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"173521","DOI":"10.1155\/2012\/173521","article-title":"Relaxation estimation of RMSD in molecular dynamics immunosimulations","volume":"2012","author":"Schreiner","year":"2012","journal-title":"Comput. Math. Methods Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1084\/jem.103.3.295","article-title":"The preparation and function of the hypertension converting enzyme","volume":"103","author":"Skeggs","year":"1955","journal-title":"J. Exp. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Expert opinion on drug discovery challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin. Drug Disc"},{"key":"B60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1021\/ja0356131","article-title":"An approach to developing a force field for molecular simulation of martensitic phase transitions between phases with subtle differences in energy and structure","volume":"126","author":"Tuble","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e01403","DOI":"10.1128\/JVI.01403-18","article-title":"Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells","volume":"93","author":"Urbanowicz","year":"2019","journal-title":"J. Virol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM All-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2009","journal-title":"J. Comput. Chem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery","volume":"8","author":"Vilar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/ATVBAHA.118.311282","article-title":"Renin-angiotensin system and cardiovascular functions","volume":"38","author":"Wu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1039\/C5MB00306G","article-title":"Molecular BioSystems protein localization vector propagation: a method for improving the accuracy of drug repositioning","volume":"11","author":"Yeu","year":"2015","journal-title":"Mol. BioSyst."},{"key":"B70","doi-asserted-by":"publisher","first-page":"16752","DOI":"10.1039\/D0NJ03611K","article-title":"\u2018Molecular docking reveals the potential of cleome amblyocarpa isolated compounds to inhibit COVID-19 virus main protease","volume":"44","author":"Zaki","year":"2020","journal-title":"N. J. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2021.661230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:05:17Z","timestamp":1620104717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2021.661230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":71,"alternative-id":["10.3389\/fchem.2021.661230"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2021.661230","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"article-number":"661230"}}